H

Hana Pharm Co Ltd
KRX:293480

Watchlist Manager
Hana Pharm Co Ltd
KRX:293480
Watchlist
Price: 10 380 KRW -0.1% Market Closed
Market Cap: 184.5B KRW
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Hana Pharm Co Ltd stock under the Base Case scenario is 15 791.87 KRW. Compared to the current market price of 10 380 KRW, Hana Pharm Co Ltd is Undervalued by 34%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
15 791.87 KRW
Undervaluation 34%
Relative Value
Price
H
Worst Case
Base Case
Best Case

Valuation Multiples

0.8
P/S
P/S
Price to Sales
0.8
vs History
96
vs Industry
74
Median 3Y
1.1
Median 5Y
1.5
Industry
2.4
Forward
0.7
More Details
8.5
P/E
P/E
Price to Earnings
8.5
vs History
96
vs Industry
40
Median 3Y
10.4
Median 5Y
10.9
Industry
20.8
Forward
7.1
More Details
7.1
P/OCF
P/OCF
Price to OCF
7.1
vs History
96
vs Industry
43
Median 3Y
9.7
Median 5Y
11.2
Industry
15.4
More Details
13.5
P/FCFE
P/FCFE
Price to FCFE
13.5
vs History
44
vs Industry
26
Median 3Y
18
Median 5Y
-25.5
Industry
22.8
More Details
0.6
P/B
P/B
Price to Book Value
0.6
vs History
96
vs Industry
70
Median 3Y
0.9
Median 5Y
1.2
Industry
2
More Details
0.9
EV/S
EV/S
Enterprise Value to Sales
0.9
vs History
96
vs Industry
73
Median 3Y
1.1
Median 5Y
1.3
Industry
2.5
Forward
0.8
More Details
1.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
1.4
vs History
96
vs Industry
77
Median 3Y
1.8
Median 5Y
2.1
Industry
4.9
More Details
6.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
6.1
vs History
93
vs Industry
43
Median 3Y
6.9
Median 5Y
7
Industry
12.7
Forward
5.4
More Details
8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
8
vs History
74
vs Industry
41
Median 3Y
8.5
Median 5Y
8.4
Industry
15.8
Forward
6.9
More Details
8
EV/OCF
EV/OCF
Enterprise Value to OCF
8
vs History
92
vs Industry
43
Median 3Y
10
Median 5Y
10.1
Industry
14
More Details
16.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
16.7
vs History
50
vs Industry
25
Median 3Y
16.7
Median 5Y
16.7
Industry
18.3
More Details
0.6
EV/IC
EV/IC
Enterprise Value to IC
0.6
vs History
96
vs Industry
71
Median 3Y
0.7
Median 5Y
1
Industry
1.7
More Details

Multiples Across Competitors

Competitors Multiples
Hana Pharm Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Hana Pharm Co Ltd
KRX:293480
179.6B KRW 0.8 8.5 6.1 8
US
Eli Lilly and Co
NYSE:LLY
779.4B USD 17.3 73.6 42.8 47.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
394B USD 4.4 28 13.1 17.2
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 7.2 20.8 13.7 15.6
CH
Roche Holding AG
SIX:ROG
236.5B CHF 4 20.6 11.5 13.6
UK
AstraZeneca PLC
LSE:AZN
177B GBP 4.2 32.6 126.9 193.8
US
Merck & Co Inc
NYSE:MRK
225.9B USD 3.5 13.2 8.9 10.5
CH
Novartis AG
SIX:NOVN
199.7B CHF 4.4 19 11.5 14.7
IE
Endo International PLC
LSE:0Y5F
167.6B USD 72.3 -57.3 267.5 670.8
US
Pfizer Inc
NYSE:PFE
142.8B USD 2.2 17.8 8.5 12.1
P/E Multiple
Earnings Growth PEG
KR
H
Hana Pharm Co Ltd
KRX:293480
Average P/E: 26
8.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
73.6
48%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
28
26%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
20.8
19%
1.1
CH
Roche Holding AG
SIX:ROG
20.6
16%
1.3
UK
AstraZeneca PLC
LSE:AZN
32.6
36%
0.9
US
Merck & Co Inc
NYSE:MRK
13.2
17%
0.8
CH
Novartis AG
SIX:NOVN
19
16%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -57.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.8
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
H
Hana Pharm Co Ltd
KRX:293480
Average EV/EBITDA: 396.1
6.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.8
30%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.1
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
15%
0.9
CH
Roche Holding AG
SIX:ROG
11.5
8%
1.4
UK
AstraZeneca PLC
LSE:AZN
126.9
9%
14.1
US
Merck & Co Inc
NYSE:MRK
8.9
9%
1
CH
Novartis AG
SIX:NOVN
11.5
5%
2.3
IE
E
Endo International PLC
LSE:0Y5F
267.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.5
3%
2.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
H
Hana Pharm Co Ltd
KRX:293480
Average EV/EBIT: 1 700.5
8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
47.2
33%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.2
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
15.6
16%
1
CH
Roche Holding AG
SIX:ROG
13.6
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
193.8
21%
9.2
US
Merck & Co Inc
NYSE:MRK
10.5
12%
0.9
CH
Novartis AG
SIX:NOVN
14.7
8%
1.8
IE
E
Endo International PLC
LSE:0Y5F
670.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.1
10%
1.2

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 242,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.